

Remarks/Arguments

Applicants have amended the specification to provide the priority claim.


The claims have been amended by cancelling all the claims, i. e. claims 1-25 and replacing them with new claims 26-47. The new claims have been presented to remove multiple dependencies and to otherwise place the claims in an appropriate U.S. format. New claims 26-47 correspond to previous claims 1-22. No new matter has been added by these amendments.

The above amendments have been made without prejudice to Applicants right to prosecute any cancelled subject matter in a timely filed continuation application.

Applicants believe the application is in condition for allowance, which action is respectfully requested.

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 100815-1 US.

Respectfully submitted,



Name:	Lucy Padget
Dated:	February 18, 2005
Reg. No.:	Limited Recognition
Phone No.:	781-839-4182

Global Intellectual Property, Patents,
AstraZeneca R&D Boston,
35, Gatehouse Drive,
Waltham,
MA 01760